Get clinical trials

{
  "data": {
    "ticker": "PFE",
    "isBiotech": true,
    "companyName": "PFIZER INC",
    "trials": [
      {
        "id": "ct-NCT04255875",
        "type": "clinical_trial",
        "ticker": "PFE",
        "date": "2026-06-12",
        "title": "Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease",
        "description": "Phase 1 | Completed | Healthy, Sickle Cell Anemia",
        "metadata": {
          "nctId": "NCT04255875",
          "status": "COMPLETED",
          "phases": [
            "PHASE1"
          ],
          "conditions": [
            "Healthy",
            "Sickle Cell Anemia"
          ],
          "interventions": [
            {
              "name": "Placebo",
              "type": "BIOLOGICAL"
            },
            {
              "name": "PF-07209326",
              "type": "BIOLOGICAL"
            },
            {
              "name": "PF-07209326",
              "type": "BIOLOGICAL"
            }
          ],
          "enrollment": 52,
          "enrollmentType": "ACTUAL",
          "sponsor": "Pfizer",
          "studyType": "INTERVENTIONAL",
          "officialTitle": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED EVALUATION OF SINGLE DOSES OF PF-07209326 IN HEALTHY PARTICIPANTS (SAFETY, TOLERABILITY, AND PHARMACOKINETICS [PK]) FOLLOWED BY AN OPEN LABEL, REPEAT DOSE EVALUATION IN SICKLE CELL DISEASE PARTICIPANTS (SAFETY, TOLERABILITY, PK AND EFFICACY)",
          "startDate": "2020-02-05",
          "startDateType": "ACTUAL",
          "completionDate": "2023-07-07",
          "completionDateType": "ACTUAL",
          "primaryCompletionDate": "2023-07-07",
          "primaryCompletionDateType": "ACTUAL",
          "hasResults": false,
          "briefSummary": "This Phase 1 first-in-human, first-in-patient, single ascending dose and multiple dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, and pharm"
        }
      },
      {
        "id": "ct-NCT05414500",
        "type": "clinical_trial",
        "ticker": "PFE",
        "date": "2026-06-11",
        "title": "Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides",
        "description": "Phase 1 | Suspended | Cutaneous T Cell Lymphoma, Mycosis Fungoides",
        "metadata": {
          "nctId": "NCT05414500",
          "status": "SUSPENDED",
          "phases": [
            "PHASE1"
          ],
          "conditions": [
            "Cutaneous T Cell Lymphoma",
            "Mycosis Fungoides"
          ],
          "interventions": [
            {
              "name": "Mogamulizumab",
              "type": "DRUG"
            },
            {
              "name": "Brentuximab vedotin",
              "type": "DRUG"
            }
          ],
          "enrollment": 10,
          "enrollmentType": "ESTIMATED",
          "sponsor": "University of Alabama at Birmingham",
          "studyType": "INTERVENTIONAL",
          "officialTitle": "Phase I Study of Mogamulizumab (M) in Combination With Brentuximab Vedotin (BV) in Previously Treated Cutaneous T Cell Lymphoma (CTCL) and Mycosis Fungoides (MF)",
          "startDate": "2023-05-01",
          "startDateType": "ACTUAL",
          "completionDate": "2027-07-31",
          "completionDateType": "ESTIMATED",
          "primaryCompletionDate": "2027-06-30",
          "primaryCompletionDateType": "ESTIMATED",
          "hasResults": false,
          "briefSummary": "This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab.\n\nThe primary objective of the study is to assess the safety and tolerabili"
        }
      },
      {
        "id": "ct-NCT07575945",
        "type": "clinical_trial",
        "ticker": "PFE",
        "date": "2026-06-11",
        "title": "A Study to Learn if a Medicine Called Itraconazole Changes How the Body Processes the Study Medicine PF-08642534 in Healthy Adults.",
        "description": "Phase 1 | Active Not Recruiting | Healthy Participant",
        "metadata": {
          "nctId": "NCT07575945",
          "status": "ACTIVE_NOT_RECRUITING",
          "phases": [
            "PHASE1"
          ],
          "conditions": [
            "Healthy Participant"
          ],
          "interventions": [
            {
              "name": "PF-08642534",
              "type": "DRUG"
            },
            {
              "name": "Itraconazole",
              "type": "DRUG"
            }
          ],
          "enrollment": 14,
          "enrollmentType": "ACTUAL",
          "sponsor": "Pfizer",
          "studyType": "INTERVENTIONAL",
          "officialTitle": "A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF SINGLE ORAL DOSES OF PF-08642534 IN HEALTHY ADULT PARTICIPANTS",
          "startDate": "2026-05-05",
          "startDateType": "ACTUAL",
          "completionDate": "2026-07-23",
          "completionDateType": "ESTIMATED",
          "primaryCompletionDate": "2026-06-26",
          "primaryCompletionDateType": "ESTIMATED",
          "hasResults": false,
          "briefSummary": "The purpose of this study is to learn if a medicine called itraconazole changes how the body processes the study medicine (PF-08642534) in healthy adults.\n\nThis study is seeking healthy participants ("
        }
      }
    ]
  }
}